Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Industry veteran with a track record of strong commercial results will oversee a team that partners with pharma and biotech companies to deliver commercialization, launch, and revenue management solutions FAIRFIELD, Conn., November 10, 2026 (Newswire.com) - Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Siino will lead a team providing best-in-class launch and revenue management services to the biopharma community. Pharma and biotech companies across the industry seek suppliers who can support them from their earliest stages, often before they have built in-house commercial, market access, and revenue management capabilities. Two Labs provides commercialization services and consulting support as these companies prepare for and execute successful launches; Riparian offers consulting, managed services, and technology to manage and protect revenue as their therapies reach patients. Together, Envision's Two Labs and Riparian businesses offer a single, connected solution spanning launch and beyond. Under Siino's leadership, clients will have a dedicated commercial partner who understands their stage of growth and can connect them with the full range of Envision's capabilities as their needs change. Siino brings extensive industry and domain experience across biopharma commercialization, market intelligence, and revenue management, along with a track record of strong commercial results. "Life sciences companies of all sizes need partners who can support them from the very start of their commercial journey," said Tom Langan, CEO, Envision Pharma Group. "Two Labs and Riparian offer solutions that are in high demand in this market. Leigh Anne combines deep domain expertise, a client-side perspective, and a proven record of driving commercial growth, making her the right leader to strengthen these partnerships and expand our presence in this important segment." Jenn Lospinoso, President, Riparian, adds, "Our clients want a partner who understands the complexities of bringing therapies to market and has the expertise to turn commercialization strategy into meaningful results. Leigh Anne knows this market well, and her leadership will help life sciences companies realize the full benefits of Two Labs' and Riparian's integrated solutions." Siino joins Envision from Spherix Global Insights, a specialized market intelligence firm serving the pharma and biotech sectors. As Chief Revenue Officer, she led commercial strategy and go-to-market expansion into new therapeutic areas and customer markets. Prior to that, she was Vice President, Sales, at IntegriChain, where she led sales strategy and execution across large, midsize, and emerging pharma and life sciences companies. Earlier in her career, she held roles at UCB and Merck. "Pharma and biotech companies need partners who move at their pace and grow with them," said Siino. "Two Labs and Riparian together address critical needs from launch through revenue management, backed by Envision's deep expertise across the entire commercialization lifecycle. I'm excited to lead a team focused on helping these companies achieve commercial success and bring their therapies to patients." Siino holds a Master of Science in Jurisprudence from Seton Hall University School of Law, with concentrations in intellectual property and in pharmaceutical and medical device law and compliance, and a BA in economics from Ramapo College of New Jersey. She is based in the Greater Philadelphia area. About Envision Pharma Group Envision Pharma Group is a global, technology-enabled solutions partner to the life sciences industry. We unleash the power of combined intelligence - human expertise and technology - to advance how scientific innovation translates into improved patient outcomes. We unite scientific expertise, strategic insight, and AI-powered technology to help clients create, communicate, and demonstrate value, accelerating access to life-changing treatments. With more than 20 years of experience and trusted partnerships with 400+ biopharma companies, including all top 20 pharma, we deliver integrated solutions across the product lifecycle, from medical communications to commercialization and compliance, through flexible models that scale to client needs. Together, we combine human insight and technology to drive smarter decisions, measurable impact, and sustainable growth. Sophie Berger, Global Head, Marketing, Envision Pharma Group. Email: [email protected]

Spherix Global Insights launches Obesity Franchise as weight management impacts commercial strategy across related markets. Oct. 5, 2026, 12:41 PM Exton, PA, Oct. 05, 2026 (GLOBE NEWSWIRE) - Spherix Global Insights, an independent market intelligence and advisory firm serving the global life sciences industry, today announced the launch of its Obesity Franchise. The launch brings Spherix's existing obesity research into a focused franchise, connecting it with the firm's established gastroenterology/MASH and nephrology/cardiorenal expertise while creating opportunities to expand its publication portfolio and advisory capabilities as treatment decisions increasingly span obesity, cardiometabolic health, and kidney disease. Obesity is increasingly influencing treatment strategies and commercial opportunities across MASH, CKD-ND, and related cardiometabolic conditions. For commercial and medical teams, this overlap raises questions about where treatment decisions intersect, how responsibilities differ across specialties, and how payer policies influence access. Spherix's Obesity Franchise places these questions within a focused research and advisory offering. The franchise connects Spherix's obesity research with expertise from its Gastroenterology and Nephrology teams. This collaboration helps clients understand the specific treatment and access considerations within obesity, MASH, and CKD-ND, while identifying where decisions across these markets intersect. Research across physician, patient, and payer perspectives examines therapy adoption and sequencing, treatment burden and persistence, as well as formulary and coverage decisions. Together, these findings help clients understand how clinical preferences, patient experiences, and access requirements influence the opportunities for new and established therapies. This integrated view also supports organizations approaching these markets through a cardiovascular-kidney-metabolic (CKM) framework. For clients, these insights support decisions about where to compete, how to differentiate, and which barriers to address. Connecting physician prescribing decisions with patient experiences and payer requirements helps teams refine brand positioning, prioritize evidence needs, and focus on engagement strategies. Coverage across related conditions also helps clients evaluate how changes in one market may influence adoption and access in another. Led by Jim Hickey, Franchise Head, Gastroenterology and Obesity, the team provides syndicated intelligence and tailored advisory support for development, launch, positioning, and market access decisions. Clients can draw on therapeutic expertise and research tailored to specific strategic questions, from understanding prescribing patterns to identifying barriers to treatment adoption and continuity. Spherix's established Nephrology Franchise, led by Kari McCarthy, provides an additional layer of expertise across the evolving obesity and cardiorenal landscape. Associated research titles examine the challenges of treating patients with non-dialysis chronic kidney disease (CKD-ND) and cardiorenal disease, including treatment patterns, unmet needs, and the clinical and access dynamics shaping adoption. Together with Spherix's obesity research, these insights give clients a broader view of how weight management is increasingly influencing treatment strategies across interconnected metabolic, cardiovascular, and kidney diseases. "Success in obesity requires understanding how clinical promise translates into prescribing, access, and sustained treatment," explained Hickey. "As opportunities extend into MASH and kidney disease, companies cannot assume that the same evidence, positioning, or engagement strategy will resonate across specialties. Expanding our research helps clients identify where those differences matter and make more informed decisions about their brands." Establishing the Obesity Franchise gives clients a clearer point of access to Spherix's research and specialists while positioning the firm to deepen its coverage of an increasingly interconnected area of care. About Spherix Global Insights Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into an integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it. The firm operates ten dedicated therapeutic franchises - Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Obesity, Oncology, Ophthalmology, Respiratory and Rheumatology - plus a Market Access team. Each franchise is staffed by hyper-focused experts who track these markets full-time, drawing on independently curated communities of vetted specialists, patients, and payers to deliver quarterly trending, launch tracking, chart audits, and KOL synthesis. Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, industry media, financial analysts, and patient advocacy groups. To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn. Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Sponsored Financial Content